Janssen Reports P-I Study (CHRYSALIS) Results of Rybrevant (amivantamab-vmjw) for Advanced Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations
- The P-I study evaluates Rybrevant as a monotx. and in combination with Lazertinib in 780 patients that showed long-term response and safety, m-OS was 23mos. after a median follow-up of 19.2mos., 2yr. OS rate of 47%, ORR (37%), m-DOR of 12.5mos. and m-PFS of 6.9mos.
- Treatment with Rybrevant resulted in consistent efficacy across post-platinum patients with EGFR exon 20 insertion mutations, 42% had sustained clinical response, and m-DoR was 7.5mos. with ongoing treatment in 13%, 7 are progression-free & 8 received treatment beyond the progression
- No new safety signals were seen, and the incidence of treatment-related AEs leading to dose interruption, reduction & discontinuation was 29%/18%/7%, respectively. The results were presented at ELCC 2023
Ref: new-rybrevant | Image: new-rybrevant
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at firstname.lastname@example.org.